Molecules and medicine / (Record no. 116)
[ view plain ]
000 -LEADER | |
---|---|
fixed length control field | 05763cam a22002894a 4500 |
001 - CONTROL NUMBER | |
control field | 964 |
005 - DATE AND TIME OF LATEST TRANSACTION | |
control field | 20200611124316.0 |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
fixed length control field | 070716s2007 njua b 001 0 eng |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 9780470227497 (pbk.) |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
International Standard Book Number | 0470227494 (pbk.) |
040 ## - CATALOGING SOURCE | |
Transcribing agency | DLC |
082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
Classification number | 615.1 |
Edition number | 22 |
Item number | C7975 |
100 1# - MAIN ENTRY--PERSONAL NAME | |
Personal name | Corey, E. J. |
245 10 - TITLE STATEMENT | |
Title | Molecules and medicine / |
Statement of responsibility, etc | E.J. Corey, B. Czakó and L. Kürti. |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Place of publication, distribution, etc | Hoboken, N.J. : |
Name of publisher, distributor, etc | John Wiley & Sons, |
Date of publication, distribution, etc | 2007 |
300 ## - PHYSICAL DESCRIPTION | |
Extent | xii, 254 p. |
Other physical details | ill. (some col.) ; |
Dimensions | 26 cm. |
500 ## - GENERAL NOTE | |
General note | Includes bibliographical references and index. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Drugs. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Molecules. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Molecular biology. |
650 12 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Pharmaceutical Preparations. |
650 22 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
Topical term or geographic name as entry element | Molecular Biology |
General subdivision | methods. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Czakó, Barbara. |
700 1# - ADDED ENTRY--PERSONAL NAME | |
Personal name | Kürti, László, |
942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
Koha item type | Books |
505 0# - FORMATTED CONTENTS NOTE | |
Formatted contents note | 1. Part i. Introduction. <br/>2. Understanding structural diagrams of organic molecules. <br/>3. Some common molecules. <br/>4. Proteins and three-dimensional protein structure. <br/>5. Some of the protein structures that appear in this book. <br/>6. Part ii. Inflammatory, cardiovascular and metabolic diseases. <br/>7. Anti-inflammatory agents. <br/>8. Acetylsalicylic acid aspirin™). <br/>9. Naproxen (aleve™). <br/>10. How do anti-inflammatory drugs work? <br/>11. Other eicosanoids in inflammation. <br/>12. An overview of inflammation. <br/>13. Celecoxib (celebrex™). <br/>14. Prednisone (deltasone™). <br/>15. Methotrexate (trexall™). <br/>16. Allopurinol (zyloprim™). <br/>17. Antiasthmatic and antiallergic agents. <br/>18. Salmeterol (serevent™). <br/>19. Fluticasone propionate (flovent™). <br/>20. Montelukast sodium (singulair™). <br/>21. Tiotropium bromide (spiriva™). <br/>22. Loratadine (claritin™). <br/>23. Type 2 diabetes. <br/>24. An overview of metabolic syndrome. <br/>25. Antidiabetic and cholesterol-lowering agents. <br/>26. Metformin (glucophage™). <br/>27. Glipizide (glucotrol™). <br/>28. Pioglitazone (actos™. <br/>29. Sitagliptin (januvia™. <br/>30. Atorvastatin (lipitor™. <br/>31. Ezetimibe (zetia™. <br/>32. Cardiovascular agents. <br/>33. Atenolol (tenormin™. <br/>34. Enalapril (vasotec™. <br/>35. Candesartan cilexetil (atacand™. <br/>36. Aliskiren (tekturna™. <br/>37. Amlodipine (norvasc™. <br/>38. Nitroglycerin. <br/>39. Clopidogrel bisulfate (plavix™. <br/>40. Digoxin (lanoxin™. <br/>41. Receptors and signaling. <br/>42. Information flow into the cell by chemical signaling. <br/>43. References for part ii. <br/>44. Part iii. Reproductive medicine. <br/>45. Oral contraceptives. <br/>46. Testosterone. <br/>47. Mifepristone (mifeprex™. <br/>48. Oxytocin (oxytocin™. <br/>49. Sildenafil (viagra™. <br/>50. Osteoporosis. <br/>51. Some aspects of osteoporosis. <br/>52. Alendronate (fosamax™. <br/>53. Calcitriol (rocaltrol™. <br/>54. Raloxifene (evista™. <br/>55. Teriparatide (forteo™. <br/>56. Glaucoma and antiulcer agents. <br/>57. Latanoprost (xalatan™. <br/>58. Ranitidine (zantac™. <br/>59. Omeprazole (prilosec™. <br/>60. References for part iii. <br/>61. Part iv. Autoimmune disease and organ transplant. <br/>62. A brief survey of the immune system. <br/>63. Immunosuppressive agents. <br/>64. Azathioprine (imuran™. <br/>65. Mycophenolate mofetil (cellcept™. <br/>66. Cyclosporin (neoral™. <br/>67. Tacrolimus (prograf™. <br/>68. Fty720 (fingolimod). <br/>69. Infectious diseases. <br/>70. Antibiotics. <br/>71. Amoxicillin (amoxil™. <br/>72. Cefaclor (ceclor™. <br/>73. Doxycycline (vibramycin™. <br/>74. Azithromycin (zithromax™. <br/>75. Ciprofloxacin (cipro™. <br/>76. Trimethoprim (triprim™. <br/>77. Amikacin (amikin™. <br/>78. Vancomycin (vancocin™. <br/>79. Linezolid (zyvox™. <br/>80. Isoniazid (laniazid™. <br/>81. Ancillary antibiotics. <br/>82. Drug resistance. <br/>83. Antiviral agents. <br/>84. On viruses and viral diseases. <br/>85. Acyclovir (zovirax™. <br/>86. Ribavirin (virazole™. <br/>87. Oseltamivir (tamiflu™. <br/>88. Zidovudine (retrovir, azt™. <br/>89. Zalcitabine (hivid™. <br/>90. Nevirapine (viramune™. <br/>91. Efavirenz (sustiva™. <br/>92. Lopinavir + ritonavir (kaletra™. <br/>93. Uk427857 (maraviroc). <br/>94. Antifungal agents. <br/>95. Amphotericin (fungizone™. <br/>96. Fluconazole (diflucan™. <br/>97. Caspofungin (cancidas™. <br/>98. Terbinafine (lamisil™. <br/>99. Antimalarial and antiparasitic agents. <br/>100. Parasitic diseases: a focus on malaria. <br/>101. Chloroquine (aralen™. <br/>102. Artemether + lumefantrine (coartem™. <br/>103. Atovaquone + proguanil (malarone™. <br/>104. Miltefosine (impavido™. <br/>105. Nitazoxanide (alinia™. <br/>106. Ivermectin (stromectol™. <br/>107. References for part iv. <br/>108. Part v. Malignant disease. <br/>109. An overview of cancer. <br/>110. Capecitabine (xeloda™. <br/>111. Carboplatin (paraplatin™. <br/>112. Vinblastine (velban™. <br/>113. Paclitaxel (taxol™. <br/>114. Cyclophosphamide (cytoxan™. <br/>115. Tamoxifen (nolvadex™. <br/>116. Irinotecan (camptosar™. <br/>117. Bleomycin (blenoxane™. <br/>118. Imatinib (gleevec™. <br/>119. Sunitinib (sutent™. <br/>120. Bortezomib (velcade™. <br/>121. Ancillary anticancer agents. <br/>122. References for part v. <br/>123. Part vi. Drugs acting on the nervous system. <br/>124. Pain and analgesia. <br/>125. Lidocaine (xylocaine™. <br/>126. Morphine (avinza™. <br/>127. Acetaminophen (tylenol™. <br/>128. Fentanyl (duragesic™. <br/>129. Sodium thiopental (sodium pentothal™. <br/>130. Gabapentin (neurontin™. <br/>131. Diazepam (valium™. <br/>132. Sumatriptan (imitrex™. <br/>133. Hypnotics (insomnia) and antismoking. <br/>134. Zolpidem (ambien™. <br/>135. Ramelteon (rozerem™. <br/>136. Varenicline (chantix™. <br/>137. The brain, neurotransmission and molecular neurotransmitters. <br/>138. Neurodegenerative and psychiatric diseases. <br/>139. Levodopa (larodopa™. <br/>140. Donepezil (aricept™. <br/>141. Antiepileptic agents. <br/>142. Antianxiety agents. <br/>143. Antidepressants. <br/>144. Antipsychotics. <br/>145. References for part vi. <br/>146. Glossary. <br/>147. Index.<br/> |
Withdrawn status | Damaged status | Not for loan | Home library | Current library | Date acquired | Source of acquisition | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
---|---|---|---|---|---|---|---|---|---|---|---|
UE-Central Library | UE-Central Library | 21.05.2018 | U.E.15199 | 615.1 C7975 | T964 | 21.05.2018 | 21.05.2018 | Books |